Personalised medicine and cancer care
The Committee on Health and Welfare has commissioned a study focusing on personalised medicine and cancer care. Since the 1990s, the number of patients diagnosed with cancer has increased by an average of 2 percent per year. The increase is partly due to the fact that we get older, expanded screening and better methods to diagnose cancer, but also due to increased exposure to risk factors. At the same time the survival of cancer patients has increased where better diagnostic methods, more effective drugs and personalised cancer treatments are parts of the explanation behind the positive trend. Personalised cancer treatments could imply cost savings as drugs are becoming more accurate and efficient. At the same time individual-based treatments have to address both legal and ethical challenges since large amounts of personal data are handled. The study will focus on: Personalised cancer treatments Cost-effectiveness Cancer and psychological stress on relatives Social, legal and ethical challenges relating to the development of cancer care
Short title:
Personalised medicine
Start date:
End date:
Project leader:
Evaluation and Research Secretariat (ERS) of the Swedish Riksdag (ERS)